Closely held PharmaJet announced that its partner, Scancell, has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma demonstrating a progression-free survival (PFS) rate of 74% at 16 months, compared to 50% PFS at 11.5 months for standard-of-care checkpoint inhibitor therapy alone.
In the SCOPE study, Scancell’s iSCIB1+ immunotherapy was delivered intramuscularly using Stratis, PharmaJet’s Needle-free Injection System. Data was presented at the ESMO Immuno-Oncology Congress 2025 on December 11, 2025. Based on these results, Scancell plans to initiate a registrational Phase 3 study in the second half of 2026 with its immunotherapy delivered with Stratis, PharmaJet’s Needle-free Injection System. Subject to regulatory outcomes and achievement of clinical endpoints, Scancell plans to advance iSCIB1+ towards potential commercialization by 2029.
In a statement, Dr. Phil L’Huillier, CEO of Scancell, commented, “PharmaJet’s Needle-free Injection System is an effective delivery device for iSCIB1+ and we are delighted with the latest results in the Phase 2 study. Patients and providers alike prefer the needle-free system over conventional needle and syringe. We have significant experience with Stratis and its ability to consistently deliver our product in a more comfortable and convenient way.”
Wouter Latour, CEO of PharmaJet, remarked, “PharmaJet is pleased to support Scancell’s SCOPE Phase 2 program and preparations for the upcoming registrational trial. With U.S. FDA 510(k) clearance and CE mark in Europe, Stratis is designed to provide consistent, reproducible intramuscular delivery of DNA-based therapies, offering a needle-free alternative to traditional injections which can be inefficient for DNA delivery, and to electroporation, which is often uncomfortable for patients. We are encouraged by the clinical progress achieved with immunotherapy administered via Stratis and we look forward to making the technology available for the development of other next-generation vaccines and immunotherapies.”
